Cartilage Degeneration Market Estimated to Reach US$16 Billion by 2027

In 2022, the global cartilage degeneration market (軟骨変性市場) was valued at US$ 12.1 billion. Forecasts indicate a robust growth trajectory, with revenues expected to reach US$ 16 billion by the close of 2027, expanding at a Compound Annual Growth Rate (CAGR) of 5.7% over the ensuing five years.

𝗚𝗲𝘁 𝗙𝗿𝗲𝗲 𝗦𝗮𝗺𝗽𝗹𝗲 𝗥𝗲𝘀𝗲𝗮𝗿𝗰𝗵 𝗥𝗲𝗽𝗼𝗿𝘁 𝗖𝗼𝗽𝘆:

https://www.factmr.com/connectus/sample?flag=S&rep_id=7738

The escalating number of joint replacement surgeries worldwide is set to propel demand for such procedures at a remarkable CAGR of 6%, surpassing other medical interventions. Cartilage degeneration, a precursor to bone diseases like osteoarthritis, has seen a significant uptick in incidence globally, fostering the demand for treatments. This trend is anticipated to persist throughout the forecast period, principally driving market growth until 2027.

Additionally, the rise in accidents and trauma cases is expected to fuel demand for cartilage repair solutions in the foreseeable future. Factors such as an aging population, escalating obesity rates, a surge in sports-related injuries, and continuous technological advancements further bolster the market's potential.

Nevertheless, the exorbitant costs associated with cartilage repair therapies coupled with unfavorable reimbursement scenarios in many regions may impede overall market expansion in the coming years.

Throughout the period from 2022 to 2027, the global cartilage degeneration market is poised to undergo moderate growth, with a CAGR of 5.7%.

𝗠𝗮𝗿𝗸𝗲𝘁 𝗞𝗲𝘆 𝗗𝗿𝗶𝘃𝗲𝘀:

Aging Population: The global demographic shift towards an aging population is a primary driver of cartilage degeneration market growth. With advancing age, individuals are more susceptible to cartilage wear and tear, leading to conditions such as osteoarthritis.

Rising Prevalence of Osteoarthritis: Osteoarthritis, characterized by cartilage degradation, stiffness, and joint pain, is one of the leading contributors to the cartilage degeneration market. As sedentary lifestyles and obesity rates rise globally, the prevalence of osteoarthritis is also increasing, fueling demand for innovative treatments.

Advancements in Medical Technology: Technological advancements in medical imaging, regenerative medicine, and minimally invasive surgical techniques have revolutionized the treatment landscape for cartilage degeneration. Novel approaches such as tissue engineering, stem cell therapy, and 3D printing offer promising solutions for cartilage repair and regeneration.

Growing Awareness and Diagnosis: Increasing awareness among patients and healthcare professionals about the importance of early diagnosis and intervention for cartilage degeneration is driving market growth. Improved diagnostic modalities and screening programs enable timely identification of cartilage abnormalities, facilitating prompt treatment initiation.

Expanding Research and Development Activities: Pharmaceutical and biotechnology companies are intensifying their efforts to develop innovative therapies for cartilage degeneration. Investments in research and development, coupled with collaborations between academia and industry, are accelerating the discovery of novel treatment modalities and therapeutic targets.

𝗙𝘂𝘁𝘂𝗿𝗲 𝗢𝘂𝘁𝗹𝗼𝗼𝗸:

Personalized Medicine: The emergence of personalized medicine approaches, including genetic profiling and biomarker analysis, is expected to enhance treatment outcomes and patient satisfaction in cartilage degeneration management.

Regenerative Therapies: Regenerative medicine holds immense potential for cartilage repair and regeneration. Stem cell-based therapies, growth factors, and tissue engineering techniques are likely to gain prominence as viable treatment options for cartilage degeneration in the future.

Integration of Digital Health Solutions: The integration of digital health solutions such as telemedicine, wearable devices, and remote monitoring platforms is anticipated to optimize patient care and treatment adherence, thereby improving clinical outcomes in cartilage degeneration management.

Healthcare Policy and Reimbursement Landscape: Evolving healthcare policies and reimbursement frameworks will play a crucial role in shaping market dynamics and access to innovative cartilage degeneration therapies. Policy initiatives promoting value-based care and patient-centered outcomes are expected to drive market growth and innovation.

Global Collaboration and Knowledge Exchange: Collaborative efforts among stakeholders, including healthcare providers, researchers, policymakers, and patient advocacy groups, are essential for advancing understanding and management of cartilage degeneration on a global scale. Knowledge exchange and interdisciplinary collaboration will facilitate the development of holistic approaches to address the multifaceted challenges posed by cartilage degeneration.

𝗥𝗲𝗾𝘂𝗲𝘀𝘁 𝗙𝗼𝗿 𝗙𝗥𝗘𝗘 𝗖𝘂𝘀𝘁𝗼𝗺𝗶𝘇𝗮𝘁𝗶𝗼𝗻 𝗥𝗲𝗽𝗼𝗿𝘁:

https://www.factmr.com/connectus/sample?flag=RC&rep_id=7738

𝗠𝗮𝗿𝗸𝗲𝘁 𝗞𝗲𝘆 𝗣𝗹𝗮𝘆𝗲𝗿𝘀:

DePuy Synthes
Zimmer Biomet
Stryker Corporation
Smith & Nephew plc
Braun Melsungen AG
Medtronic plc.
Johnson & Johnson (DePuy Synthes)
Osiris Therapeutics Inc.
Vericel Corporation
Anika Therapeutics Inc.
MEDIPOST Co. Ltd.
CONMED Corporation
Arthrex Inc.

𝗖𝗼𝗺𝗽𝗲𝘁𝗶𝘁𝗶𝘃𝗲 𝗟𝗮𝗻𝗱𝘀𝗰𝗮𝗽𝗲:

Leading players in the cartilage degeneration sector are dedicated to innovating novel solutions for cartilage repair and restoration, aiming to expand their market reach.

One such player, Cytonics, a biotech company specializing in osteoarthritis therapeutics, is spearheading the development of a blood protein designed to inhibit destructive enzymes responsible for cartilage degeneration. Their flagship product, CYT-108, is an advanced variant of Alpha-2-macroglobulin, engineered to facilitate cartilage repair by neutralizing these enzymes.

Moreover, companies within the cartilage degeneration industry (Marché de la dégénérescence du cartilage) are actively pursuing regulatory approvals to bolster their market presence and bolster revenue streams.

In a significant development, CartiHeal Ltd., an Israeli firm specializing in cartilage defect implants, announced in March 2022 that its Agili-C™ implant had received Premarket Approval (PMA) from the U.S. Food and Drug Administration (FDA). This regulatory milestone was achieved following the successful outcomes of a two-year Investigational Device Exemption (IDE) clinical study.

𝗕𝗿𝗼𝘄𝘀𝗲 𝗙𝘂𝗹𝗹 𝗥𝗲𝗽𝗼𝗿𝘁 @ https://www.factmr.com/report/cartilage-degeneration-market

𝗠𝗮𝗿𝗸𝗲𝘁 𝗞𝗲𝘆 𝗦𝗲𝗴𝗺𝗲𝗻𝘁𝗮𝘁𝗶𝗼𝗻:

By Procedure :
Joint Replacements
Chondroplasty
Osteochondral Transplants
Microfracture
Meniscus Transplants
Cell-based Cartilage Resurfacing
Autologous Chondrocyte Implantation
Others

By Application :
Knees
Hips
Others

By Treatment Delivery Channel :
Hospitals
Academic & Research Institutes
Specialty Clinics
Ambulatory Surgical Centers
Others

By Region :
North America
Latin America
Europe
APAC
MEA

𝗘𝘅𝗽𝗹𝗼𝗿𝗲 𝗠𝗼𝗿𝗲 𝗥𝗲𝗹𝗮𝘁𝗲𝗱 𝗦𝘁𝘂𝗱𝗶𝗲𝘀 𝗣𝘂𝗯𝗹𝗶𝘀𝗵𝗲𝗱 𝗯𝘆 𝗙𝗮𝗰𝘁.𝗠𝗥 𝗥𝗲𝘀𝗲𝗮𝗿𝗰𝗵:

Knee Cartilage Repair Market:

https://www.factmr.com/report/knee-cartilage-repair-market

Age-related Macular Degeneration Market:

https://www.factmr.com/report/age-related-macular-degeneration-market

Polyneuropathy Treatment Market:

https://www.factmr.com/report/polyneuropathy-treatment-market

𝐂𝐨𝐧𝐭𝐚𝐜𝐭:
US Sales Office :
11140 Rockville Pike
Suite 400
Rockville, MD 20852
United States
Tel: +1 (628) 251-1583
E-Mail: sales@factmr.com

𝐀𝐛𝐨𝐮𝐭 𝐅𝐚𝐜𝐭.𝐌𝐑
We are a trusted research partner of 80% of fortune 1000 companies across the globe. We are consistently growing in the field of market research with more than 1000 reports published every year. The dedicated team of 400-plus analysts and consultants is committed to achieving the utmost level of our client's satisfaction.

This release was published on openPR.